Page 14 - Practical Approaches to Managing Castration-Resistant Prostate Cancer (CRPC)

Bone Health in nmCRPC

Because ADT is associated with bone loss and risk for osteoporosis and fracture,
lifestyle, diet, and pharmacologic measures may be taken to maintain bone health.
As stated in the 2010 Canadian clinical practice guidelines for managing osteoporosis,
bisphosphonates and denosumab maintain bone mineral density in men undergoing
androgen-deprivation therapy. Please refer to the guidelines for osteoporosis diagnosis
and management strategies.

Papaioannou A, Morin S, Cheung AM, et al.; Scientific Advisory Council of Osteoporosis
Canada. 2010 clinical practice guidelines for the diagnosis and management of
osteoporosis in Canada: summary. CMAJ. 2010 Nov 23;182(17):1864-73.
http://www.cmaj.ca/content/182/17/1864.long

Note, it is important to differentiate the use of bisphosphonates and denosumab in
the non-metastatic setting from use in the setting of bone metastasis. The approved
agents, indicated uses, and doses differ.

Practical Approaches to Managing CRPC 11